Hypertension and nephrology

[Thomas G. Pickering (1940–2009) ]

KÉLES Ede

JUNE 25, 2015

Hypertension and nephrology - 2015;19(03)

COMMENTS

0 comments

Further articles in this publication

Hypertension and nephrology

[Hungarian data about the ramipril based free or fixed doses combination therapy in connection with patients adherence]

SIMONYI Gábor

[In the treatment of chronic diseases an appropriate therapeutic effect is only achieved with a long-term medication. Hypertension is no exception, because to achieve target blood pressure is of outstanding importance for the prevention of cardiovascular complications. The use of fixed drug combinations according to national and international data increases the patients adherence by 20 percent. In our article we present the one year patients adherence treated with ramipril and amlodipine free combination, ramipril/amlodipine fixed combination and ramipril/hydrochlorothiazide fixed combination in hypertension.]

Hypertension and nephrology

[A Practical Guidance to the Diagnostics and Treatment of Hyponatremia]

FORDÍTOTTÁK: Cseprekál Orsolya, KÓBOR Krisztina, KIS Éva, BRASNYÓ Pál, HARIS Ágnes, REUSZ György

Hypertension and nephrology

[Additions and Explanations to “A Practical Guideline to the Diagnostics and Treatment of Hyponatremia” ]

DEÁK György, HARIS Ágnes

Hypertension and nephrology

[The use of beta-blockers in Hungary 2007-2014 based on data from National Health Insurance]

BARNA István, GYURCSÁNYI András

[disease, various rhythm disturbances, migraine, essential tremor case, addition to the treatment of endocrine disorders caused tachycardia and also may be used in the treatment of systolic and diastolic heart failure. Using the National Health Insurance Fund (NHIF) database, we analyzed changes in the turnover of beta-blockers used domestically between 2007 and 2014. At the beginning of the period more than 50% was metoprolol as the used active ingredient, the end of the period, nebivolol became the most frequently assigned active agent betablocker (29%). Besides nebivolol the use of bisoprolol and carvedilol increased, among the “old” beta-blockers the use of pindolol, bopindolol continuously decreases, propranolol and sotalolol consumption stagnant after the initial small decrease. Metabolic syndrome, disorders of carbohydrate metabolism, in case of sleep apnea the advantage of nebivolol is accompanied by the status of enhanced sympathetic activity and consequent reduction of RAS activation. Vasodilation, inhibition of plaque formation, reduction of platelet aggregation and anti-proliferative effects of nebivolol are its unique characteristics in the beta-blocker group. Improves insulin sensitivity, thus it is not characterized by a long-term side effects that cause diabetes. Effective reduction in the central blood pressure with nebivolol is likely to reduce the risk of complications in stroke and other related central blood pressure. Therefore, if the recommendations of the international and domestic support for considering it is not surprising that the use of metoprolol reduced such a large extent and how nebivolol covered the significant majority of the entire domestic beta-blockers market. Carvedilol was before the second and currently has become the 3rd or 4th most frequently used beta blocker. The decrease in the use of metoprolol undoubtedly caused by change in the recommendations, getting out of the subsidized products, and the appearance of the above known, new effective drugs.]

Hypertension and nephrology

[I Have Brought a Case ]

KISS István

All articles in the issue

Related contents

Lege Artis Medicinae

[The Identity of Psychiatrists – a Criticism of Psychiatry by Thomas Szasz]

KELEMEN Gábor